The tweet was deleted by the author.
But we saved everything 🙂.
Corbus Pharmaceuticals Holdings, Inc. has appointed Leonardo Viana Nicacio, M.D., as its new chief medical officer.
Dr. Nicacio joins Corbus Pharmaceuticals Holdings, Inc. with over 20 years of pharmaceutical industry experience, including a key role in bringing TIVDAK to market for metastatic cervical cancer. His leadership is expected to drive the company’s clinical and medical affairs efforts as it advances its therapeutic portfolio. Further details can be accessed through the company’s official channels.
Corbus Pharmaceuticals Holdings, Inc. recently unveiled updated Phase 1/2 data for its CRB-701 program targeting HPV positive oropharyngeal squamous cell carcinoma (OPSSC). The company has outlined a focus on advancing its pipeline in this oncology indication. The appointment of Dr. Nicacio comes as Corbus expands its clinical development efforts.